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SUMMARY 
Background: A body of biochemical evidence suggests that abnormal 
phospholipid metabolism may play a role in the etiology of schizophrenia, and 
possibly, other psychiatric and neurological diseases. Niacin, a B-complex vitamin, 
induces prostaglandin synthesis, vasodilatation, and skin flushing when applied as a 
solution on the skin or taken orally. In schizophrenia, diminished or absent skin 
response to niacin represents a robust finding.  
Results: Attenuated niacin skin-flush response has been analysed as a potential 
biochemical marker of impaired prostaglandin signaling in schizophrenia. 
Diminished skin redness after topical application of niacin might be caused by a 
reduced level of the precursor arachidonic acid in the peripheral membranes, 
increased activity of the enzyme phospholipase A2, abnormal expression of niacin or 
prostaglandin receptors, or poor vasomotor activity of cutaneous capillary walls. 
Heritability estimates established in several studies support niacin skin flush 
response as a vulnerability trait for the development of psychosis. However, the 
exact mechanism of a reduced skin flush, the possible influence of the long-term use 
of antipsychotics, and the usefulness of the test for diagnostic purpose are not clear 
yet.  
Conclusions: Niacin skin flush test is a simple, non-invasive and easily 
replicable method in the research of schizophrenia. The studies investigating niacin 
flushing in schizophrenia are numerous but incoherent regarding methods of niacin 
application and evaluation of the results. New studies, controlling adequately for 
age, sex, drug abuse, diet, as well as genetic factors that may influence the intensity 
and reaction time, are necessary to clarify the usefulness of niacin testing in 
psychiatry. 
Key words: niacin skin-flush test – schizophrenia - metabolic cascade of 
arachidonic acid - polyunsaturated fatty acids - cell signaling 
*  *  *  *  *  
INTRODUCTION 
Schizophrenia is a neurodevelopmental and 
neurodegenerative disease characterized by the 
disturbance of multiple neurotransmitter signaling 
pathways. Since long chain polyunsaturated fatty 
acids (LC-PUFAs) are essential for normal 
development, structure and function of the brain, it 
is highly probable that a disturbance of their 
metabolism participates in the etiology of schizo-
phrenia, depression and other mental diseases. The 
human body has lost the ability of de novo 
synthesis of LC-PUFAs, therefore, they have to be 
present in the diet. Linoleic acid (LA, 18:2n-6) and 
alpha-linolenic acid (ALA, 18:3n-3) are essential 
fatty acids (EFAs) composed of 18 carbon atoms. 
Symbols n-3 and n-6 are synonyms for the terms 
ω-3 and ω-6 that indicate the location of the last 
double covalent bond in the fatty acid molecule, 
beginning at the end of the carbon chain. The 
EFAs are a substrate for fatty acid desaturases and 
elongases that can metabolize them into forms with 
more unsaturated bonds and longer chains. These 
forms may be incorporated into membrane 
phospholipids. The release of arachidonic acid 
(AA, 20:4n-6), docosahexaenic acid (DHA, 22:6n-
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3) and other fatty acids from the membrane 
phospholipid molecules (which are structural 
components of biological membranes) constitutes a 
part of neuronal impulse transmission. The relea-
sed fatty acids, particularly AA, and their derivates 
(prostaglandins, leukotrienes, thromboxanes) are 
important signaling molecules, but these sub-
stances are also recognized mediators of inflamma-
tion. Neuronal membranes are rich in DHA 
(~50%) (Singh 2005), particularly in the cytosolic 
portion of the phospholipid double layer, indi-
cating an important role of this fatty acid in the 
structure and function of neurons. The role of 
DHA has been recognized during pre-natal 
development. In the rat brain, the accumulation of 
DHA followed the period of active neurogenesis 
and synaptogenesis (Yavin 2006). The DHA/AA 
(n-3/n-6) ratio is important in the maintenance of 
an appropriate level of biological membrane 
fluidity, which is essential for ion channels 
function, membrane receptor activity, release of 
neurohormones, i.e. the signaling processes of 
every cell. Disruption of multiple neurotransmitters 
in schizophrenia (dopamine, serotonin, norepine-
phrine, epinephrine, glutamate, GABA-ergic) 
supports the phospholipid hypothesis that places 
neuronal membranes and membrane – related pro-
cesses in the center of the pathophysiology of this 
disease (Skosnik & Yao 2003, du Bois et al. 2005). 
Fatty acids in the membranes are bound to the 
trivalent alcohol glycerol within the phospholipid 
molecules; during neuronal transmission they are 
released by the phospholipase (PLA) group of 
enzymes. AA and DHA are incorporated in the 
phospholipid molecules mostly at the position sn-2 
(Figure 1); in their release from the membrane the 
phospholipase A2 family (PLA2) is engaged. 
Cytosolic, calcium – dependent phospholipase A2 
(cPLA2, product of PLA2G4A gene, 1q25) 
catalyses mostly the release of AA, while calcium 
– independent phospholipase A2 (iPLA2, product 
of PLA2G6A gene, 22q13.1) participates in the 
release of DHA (Green et al. 2008). After releasing 
the fatty acid from the sn-2 position, the remaining 
lysophospholipid may act as an important signaling 
molecule as well as a mediator for phagocyte 
infiltration in the inflammatory response (Zhang et 
al. 2007). 
 
 
Legend: AA-arachidonic acid; DHA– docosahexaenoic acid; PLA2-phospholipase A2; 
Figure 1. Deacylation of arachidonic or docosahexaenoic acid by phospholipase A2 
 
Enzymes of the PLA2 family work in the 
areas of neuronal membranes that contain 
monoamine receptors and are directly linked to 
neurotransmission. Numerous studies have 
indicated that a deficit of AA and n-3 group fatty 
acids in the membranes of peripheral and central 
cells of schizophrenic patients may be casually 
related to an increased activity of PLA2 enzymes 
(Gattaz et al. 1987, Ross et al. 1997, Barbosa et al. 
2007), although dietary factors (Calder 2006, Peet 
2006, Rapoport 2008), effect of medications (Chen 
et al. 2008), oxidative stress (Mahadik et al. 2001), 
and desaturase abnormalities (Nakada et al. 1990, 
Williard et al. 2001) have also been suggested as 
causative factors of FA deficiencies. As a 
consequence of an increased PLA2 activity there 
would follow an increased release of LC-PUFAs 
from membrane phospholipids, increased synthesis 
of pro-inflammatory mediators (AA derivates), 
augmented peroxidation of lipids and free radicals 
formation; finally resulting in an imbalance of 
membrane phospholipid fatty acids turnover. 
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Different studies have suggested a disturbance of 
metabolic cascade that starts with PLA2 activity in 
patients suffering from schizophrenia, bipolar 
disorder and depression, and re-establishment of 
the equilibrium following continuous long-term 
(but not acute) antipsychotic drug treatment 
(McNamara et al. 2006).  
No highly specific biochemical tests that could 
contribute to the diagnosis of mental illnesses have 
been developed so far. However, a series of studies 
have shown attenuated response (no flushing) after 
oral or cutaneous application of niacin in 24 – 90% 
of patients with schizophrenia. This phenomenon 
has been the core of the hypothesis about the 
phospholipid disorder in schizophrenia (Messa-
more 2003). The aim of this paper is to provide an 
overview of published data regarding the 
application and results of niacin testing in patients 
suffering from schizophrenia and other mental 
illnesses in order to evaluate its potential 
diagnostic value.  
 
MECHANISM OF NIACIN ACTION 
Niacin, also known as nicotinic acid, is a 
water-soluble B complex vitamin. Being a 
precursor of nicotinamide adenine dinucleotides 
(NADH, NAD, NAD+) and nicotinamide adenine 
dinucleotide phosphate (NADP), niacin has an 
important role in many metabolic pathways. Niacin 
derivates participate in detoxication processes, 
DNA repair, and synthesis of steroid hormones in 
the suprarenal gland. The human liver can 
synthesize niacin from the essential amino acid 
tryptophan; it takes 60 mg of tryptophan to 
synthesize 1 mg of niacin (Jacobson 2007). Gross 
alimentary deficit of niacin can cause pellagra, 
while a moderate deficit decreases the intensity of 
metabolism and causes a decreased sensitivity to 
coldness. Possible side effects of therapeutic doses 
of niacin are dry mouth and skin rash, gastro-
intestinal disturbance, arrhythmia, hyperglycemia, 
hyperuricaemia, while high doses can cause 
macular and retinal alterations. However, the most 
frequently observed side effect of niacin is skin 
flushing following oral or cutaneous application of 
niacin (Murrell & Taylor 1959). 
Niacin exhibits its action by binding to 
appropriate receptors in skin macrophages and 
epidermal Langerhans cells (Bosveld-van Haandel 
et al. 2006, Smesny et al. 2007). That is followed 
by the synthesis and release of prostaglandins D2 
and E2 (PGD2 and PGE2) (Figure 2). Serum 
concentration of prostaglandins following niacin 
priming can be increased up to several hundred 
times (Hudson et al. 1997, Nilsson et al. 2006).  
 
 
Legend: PLA2-phospholipase A2; AA-arachidonic acid; 
COX-2 – cyclooxygenase-2; PGG2-prostaglandin G2; PGH2-
prostaglandin H2; PGD2-prostaglandin D2 
Figure 2. The part of the metabolic cascade of 
arachidonic acid 
 
The precursor molecule, pivotal for 
prostaglandin synthesis, is AA (Ward et al. 1998, 
Nilsson et al. 2006). AA is released from 
membrane phospholipids by the action of PLA2 
enzyme and is further metabolized into 
prostaglandin molecules by the action of 
cyclooxygenase-2 (COX-2) (Tavares et al. 2003, 
Nilsson et al. 2006). Prostaglandins stimulate the 
production of cyclic AMP, which causes relaxation 
of smooth muscles in skin capillary walls, and 
consequent vasodilatation (Hudson et al. 1999 
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Messamore 2003), flushing and edema. Therefore, 
abnormalities within the PLA2/COX2 cascade 
pathway may affect the flush response to niacin 
(Maclean et al. 2003). Niacin non-responsiveness 
may, among other possibilities, indicate the 
disturbance of the membrane phospholipid 
metabolism that results in a decreased 
concentration of AA, which is an indispensable 
precursor of prostaglandins (Glen et al. 1996, 
Smesny et al. 2007). 
 
METHODS OF NIACIN APPLICATION 
AND EVALUATION OF SKIN RESPONSE 
Murrell & Taylor (1959) discovered the 
body’s response to niacin. While attempting to 
treat patients with schizophrenia with high oral 
doses of niacin (up to 3 g daily), Hoffer (1962) 
noticed an unusually high tolerance against its skin 
flush effects. Altered skin response to niacin in 
patients with schizophrenia was also noticed 
following oral application of lower doses of niacin 
(from 25 mg to 250 mg) (Fiedler et al. 1986, 
Horrobin 1980). Ward et al. (1998) introduced the 
local application of methyl-nicotinate (skin-
permeable ester of nicotinic acid) via a plastic strip 
with four pockets containing absorbent paper that 
was attached to the volar side of the lower arm. 
This method of application greatly reduced the 
systemic adverse effects of oral application as well 
as suspiciousness and discomfort of the patients. It 
further reduced the duration of the test and enabled 
a more objective evaluation of the test results 
(Figure 3). An advantage of the local application of 
niacin is the possibility of simultaneous application 
of solutions of different concentrations (0.1 M; 
0.01 M; 0.001M; 0.0001M). It offers a possibility 
to determine the optimal concentration for diffe-
rentiation between tested subjects and controls. 
The effect of oral niacin test was evaluated by 
visual inspection of facial and upper body skin 
flushing (Horrobin 1980), by skin temperature 
measurement (Fiedler et al. 1986), by measurement 
of temperature change in the ear lobe (Rybakovski 
& Weterle 1991), or by photoplethysmography (a 
method of determination in which the intensity of 
light reflected from the skin surface and the red 
cells below is measured to determine the blood 
volume of the respective area) (Wilson & Douglass 
1986), while Hudson et al. (1997) introduced the 
thermal index, i.e.the ratio of skin vs. body 
temperature. The increase of skin temperature of  
 
Legend:   A) weak (0.1M) and negative (0.01M) skin response  
                B) positive skin responses 
Figure 3. Niacin skin flush response (after applying 
0.01M and 0.1M niacin solution for 5 min) 
 
1.5 to 2ºC at the outer rim of the ear (pinna) was 
considered to be a positive niacin response. After 
the introduction of local application of niacin, the 
scales that define the intensity of the response were 
applied for skin redness evaluation. Ward et al. 
(1998) proposed the score 0 to 3 (0=no erythema, 
1=incomplete erythema, 2=complete erythema 
with the definite area of patch, 3= erythema plus 
edema beyond the area of patch), and Berger & 
McGorry (2001) score 1 to 7 (1 defines no skin 
reaction while 7 defines visible edema that starts to 
spread out or edema bigger than the patch area). 
Niacin solution was kept on the skin for no longer 
than 5 minutes, and the evaluation was done in five 
minutes intervals, up to 30 minutes after patch 
removal. Puri et al. (2002) attempted, together with 
visual inspection, to further objectify the method 
by a volumetric biochemical niacin flush-based 
index. The intensity of skin flushing after the 
application of solutions containing four different 
niacin concentrations was monitored continuously 
for 20 minutes. Smesny et al. (2001) were the first 
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to quantify skin erythema following niacin 
application by optical reflection spectroscopy (a 
simple and quick method for the quantification of 
colour intensity, suitable for the determination of 
changes in skin reddening due to local 
vasodilatation). This method was applied in their 
latter studies (Smesny et al. 2003, 2004, 2005, 
2007). Messamore et al. (2003) evaluated the 
vasodilatory effect on the skin after applying a 
niacin solution (alpha-methyl nicotinate - AMN) 
by laser Doppler flowmetry (a method of non-
invasive, continuous measurement of microcir-
culation), and found a significant difference 
between schizophrenic patients and healthy 
controls. EC50 (the molar concentration of an 
agonist, which produces 50% of the maximum 
possible response for that agonist) for AMN was 
significantly elevated in the schizophrenia group. 
Based on these results the authors suggested 
reduced pharmacological sensitivity to niacin in 
schizophrenia patients i.e. abnormalities in enzy-
mes, receptors, or signal transduction mechanisms 
that affect synthesis, release, or response to 
vasodilatory prostaglandins.  
There are a number of factors that may modify 
the intensity of niacin response: concentration of 
applied solutions, duration of exposure, duration of 
evaluation, as well as methods for evaluation of 
test results. Smesny et al. (2003) established an 
important interaction of the niacin concentration 
and time of evaluation (i.e. time elapsed since the 
beginning of patch application) in patients having 
their first psychotic episode (p<0.001), using two 
different methods of evaluation (visual inspection 
and optical reflection spectroscopy). Cyhlarova et 
al. (2007) obtained the same results while testing 
niacin response in dyslexic patients. Tavares et al. 
(2003) also observed the combined effect of 
concentration and time. In their study, significant 
differentiation between schizophrenic patients and 
healthy controls was achieved only with 0.001M 
concentration of niacin at time intervals of 10, 25 
and 30 minutes from the beginning of the 
application. Cychlarova et al. (2007) applied the 
niacin patch for 60 seconds; Smesny et al. (2005) 
applied it for 90 seconds, while in most of the 
other studies the niacin patch was removed after 5 
minutes (Ward et al. 1998, van Haandel et al. 
2006, Liu et al. 2007). As far as the duration of 
evaluation is concerned, Ward et al. (1998) 
established the differentiation between test and 
control subjects by scoring the redness after niacin 
solutions were applied for five minutes, and then 
removed. Smesny et al. (2003) established 
significant differentiation between investigated 
groups 11 minutes, and Puri et al. (2001) 15 
minutes after patch removal. The method of skin 
erythema evaluation may further influence the 
results of niacin testing. That is why Smesny et al. 
(2003) combined two methods of niacin response 
verification: visualization by scoring the intensity 
of response at the 1-7 scale (Berger & McGorry 
2001), and optical reflection spectroscopy, to 
obtain best validity of the results. When only 
erythema, but no edema was present, the two 
methods were in good correlation, but with the 
development of edema that appeared earlier when 
higher concentrations (0.1M and 0.01M) were 
applied, the verification of erythema by optical 
reflection spectroscopy was impaired, and only the 
descriptive visual method enabled successful 
differentiation between the two groups of subjects. 
The recent study of Kerr et al. (2008) revealed 
excellent inter- and intra-rater reliability of the 12-
min topical niacin test sensitivity using visual 
evaluation (7-point descriptive scale) and the 
calculation of the niacin sensitivity score. Four 
different concentrations of the niacin solution were 
simultaneously applied (0.1 M; 0.01 M; 0.001M; 
0.0001M) and rated at four time-points (3-min 
intervals) by three independent raters.  
Prior to niacin sensitivity testing, medical 
examination and history taking is necessary in 
order to establish the disease and relevant 
pharmacotherapy that might skew the results of the 
niacin test. Individuals suffering from skin 
conditions and/or diseases (eczema, psoriasis) were 
usually excluded from testing (Ward et al. 1998, 
Smesny et al. 2005, Smesny et al. 2007) as well as 
those individuals who recently have used non-
steroid anti-inflammatory drugs (Ward et al. 1998, 
Nilsson et al. 2006) since they might interfere with 
prostaglandin synthesis (inhibition of the 
cyclooxygenase-2).  
 
THE RESULTS OF STUDIES OF NIACIN 
SENSITIVITY IN PATIENTS WITH 
SCHIZOPHRENIA AND OTHER 
PATIENTS  
Many studies have investigated altered skin 
response to niacin in patients with schizophrenia 
(Table 1). Results of niacin testing were used as a 
potential marker of PUFAs deficiency, therefore 
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also of impaired membrane phospholipid 
metabolism. Attenuated or absent skin flushing in 
patients with schizophrenia was explained by a 
deficit in the synthesis of prostaglandins (Feldberg 
1976, Horrobin 1977). Therefore, Horrobin (1980) 
proposed the niacin test as an objective bio-
chemical diagnostic parameter. After delineation of 
the impact of the fatty acid content and altered 
phospholipid metabolism to physiological roles of 
cellular membranes (receptor function and signal 
transduction), the membrane phospholipid hypo-
thesis in the etiology of schizophrenia emerged 
(Horrobin 1998). Evidence for altered 
phospholipid metabolism in schizophrenia 
includes: i) increased activity of PLA2 enzyme, 
pivotal for deacylation of phospholipid molecules 
and the release of fatty acids, was found in serum, 
plasma, blood cells and brain tissue of 
schizophrenic patients (Gattaz et al. 1987, Ross et 
al. 1997, Barbosa et al. 2007); ii) reduced level of 
PUFAs (particularly AA and DHA that are 
abundant in the central nervous system) in the 
peripheral cell membranes of patients with 
schizophrenia (Mahadik et al. 1994, Peet et al. 
1998, Arvindakshan et al. 2003); iii) nuclear 
magnetic resonance images of untreated patients 
indicated an increase in the nervous cell's 
membrane phospholipid disintegration (Pettegrew 
et al. 1991, Williamson et al. 1996, Peet 2002).  
In two studies there was complete absence of 
skin flushing in both patients with schizophrenia 
and healthy controls, probably because low, 
insufficient oral doses of niacin were taken (25 mg 
and 100 mg) (Wilson & Douglass 1986, Fiedler et 
al. 1986). In a study by Fiedler et al. (1986) 
alcoholics in abstinence were also tested, but they 
too displayed no response to niacin . Tavares et al. 
(2003) found a difference in skin response between 
patients with schizophrenia and healthy controls, 
but less than in some previous studies (skin 
flushing response after niacin priming was absent 
in only 23% of patients with schizophrenia and in 
14% of healthy controls). Nilsson et al. (2006), 
found no significant difference in skin response 
between the groups following oral niacin 
application, but measurements of the skin and body 
temperature revealed a delay of peak response in 
the diseased subjects, which was a consequence of 
the delayed vasodilatatory response. Niacin testing 
was also conducted in healthy relatives of patients 
with schizophrenia (Waldo 1999, Shah et al. 1999, 
Nikolov et al. 2002, Lin et al. 2007, Smesny et al. 
2007), and in patients experiencing the first 
psychotic episode that met criteria for 
schizophrenia-like psychosis (Table 1) (Smesny et 
al. 2003, 2005); the results were contradictory. 
While some studies reported a significantly weaker 
niacin–induced skin response in the first line 
relatives of patients with schizophrenia than in 
healthy controls (Waldo 1999, Shah et al. 1999, 
Lin et al. 2007), other studies did not find 
significant differences (Nikolov et al. 2002, 
Smesny et al. 2007). Smesny et al. (2003) 
compared the niacin–induced skin response in 
first-episode patients and controls and found a 
significantly weaker niacin response in patients. A 
later study by Smesny et al. (2005) that included 
both first-episode and chronic patients with 
schizophrenia , and their age and gender matched 
healthy controls, found no group difference 
between the skin response of first-episode and 
chronically ill patients. The difference in the skin 
response was significant between first-episode 
patients and controls. At the same time, the 
difference between the chronically ill and the 
control groups was not due to the less intense skin 
response in the age-matched control individuals. 
Tavares et al. (2001) found a weaker niacin–
induced skin response in unipolar depression 
patients than in healthy controls, although the 
difference was not statistically significant. In their 
study Rybakowski & Weterle (1991) found the 
delayed vasodilatatory response following niacin 
application, although erythema appeared in 100% 
of depressive patients. Bosvel van Haandel et al. 
(2006) found no statistically significant difference 
in the niacin–induced skin response between 
depressive patients and healthy controls. Hudson et 
al. (1997), Maclean et al. (2003), Liu et al. (2007) 
tested bipolar disorder patients, and only Maclean 
et al. (2003) found a weaker skin response in 
bipolar disorder patients; on the contrary, Hudson 
et al. (1997), reported a stronger niacin–induced 
skin response in their bipolar patients. Puri & 
Singh (2002) in their autism study found no 
statistically significant difference in the skin 
erythema intensity between autistic subjects and 
healthy controls, while the studies on dyslexic 
patients (Cychlarova et al. 2007), social phobia 
(Katzman et al. 2003), and Huntington disease 
patients (Puri, 2001) reported a significantly 
weaker niacin–induced skin response when 
compared to healthy controls, although to a lesser 
extent than in schizophrenic patients (Table 2). 
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Table 1. Summary of niacin skin-flush studies in schizophrenia, first psychosis, bipolar disorder and major depression 
Patients Cont. Niacin response -  Method of 
evaluation diagnosis N N 
Dose Appli-cationd absent or diminished skin-flushing 
Reference 
SCH - - 3 g oral no quantification Hoffer 1962 
SCH - - 250 mg oral in about 80% of SCH Horrobin 1980 
SCH  126 - 200 mg oral 52% of SCH  Glen et al. 1996 
SCH 24% SCH,  
major depression 
33 
18 
- 
- 200 mg oral 0% depressed patients 
Rybakowski & 
Weterle 1991 
SCHa 35 22 10-4-10-1 M local 83% SCH; 23% controls;  at 10-2 M; p<0.0001 Ward et al. 1998 
SCHa 16 p=0.0085 
major 
depressiona 
17 16 10-1 M local no significant difference 
Bosveld-van 
Haandel et al. 2006
SCH medicateda 
SCH unmedicateda 
32 
24 18 10
-4-10-1 M local significant in both SCH groups  at 10-3-10-1 M Shah et al. 2000 
SCHa 21 20 10-4-10-1 M local 90% SCH; 25% controls;  at 10-3 M; p<0.0001 Puri et al. 2001 
SCHa 
 BPDa  
61 
18 40 10
-3-10-1 M local 49.2% SCH; 11.1% BPD; 7.5% controls; after 10 min, at 10-2 M; p<0.001 Liu et al. 2007 
SCH 30 17 200 mg oral no significant difference Nilsson et al. 2006
first psychosisb 25 25 10-4-10-1 M local significant difference at all conc. Smesny et al. 2003
1st degree relatives 
of SCH  patientsa 20 - 10
-4-10-1 M local 40% of subjects Waldo 1999 
SCHa   1st degree 
relativesa 
153 
287 94 10
-3-10-1 M local p<0.05 after 5 min and after 10 min at 10-2 M (df=2) Lin et al. 2007 
SCH–simplex fam. a,e 
SCH-multiplex fam. a,f 
176 
311 - 
visual 
inspection 
SCH–simplex fam. a,e 
SCH-multiplex fam. a,f 
176 
311 
94 
94 
10-3-10-1 M local p<0.006 at 10-1 M after 5-15 min Chang et al. 2009 
SCH 9 8 25 mg oral no significant difference Fiedler et al. 1986skin 
temp. SCHunipolar 
depression 
33 
18 - 200 mg oral delayed response in both groups 
Rybakowski & 
Weterle 1991 
PPc of 
earlobe 
skin 
SCH 16 18 100 mg oral no significant difference Wilson & Douglas 1986 
SCH 
BPD 
28 
18 28 200 mg oral 
42.9% SCH; 6% BPD; 0% controls; 
p<0.0001 Hudson et al. 1997
SCH 23 30 200 mg oral 43% SCH; 3% controls; p<0.01 Hudson et al. 1999
thermal 
index 
SCH 30 17 200 mg oral delayed response; p=0.002 Nilsson et al. 2006
SCH 27 26 10-4-10-1 M local p=0.0037 for total skin response  (at all conc.) Puri et al. 2002 
SCH 23 p< 0.05 at all conc. after 5-20 min 
volumetric 
niacin 
response 
BPD 20 
34 10-3-10-1 M local 
p<0.05 at 10-3 M after 5-20 min 
Maclean et al. 
2003 
first psychosis 25 25 10-4-10-1 M local p=0.013 at 10-4; p<0.001 at 10-3 M Smesny et al. 2003 
first psychosis 32 32 10-3-10-1 M local p<0.05 at all conc. after 3, 6, and 9 min 
multiepisode SCH 32 32 10-3-10-1 M local no significant difference 
Smesny et al. 
2005 
SCH 19 19 p<0.05 at all conc. after 3, 6, and 9 min 
optical 
reflection 
spectro-
scopy 
1st degree relatives 21 21 
10-3-10-1 M local 
no significant difference 
Smesny et al. 
2007a 
SCH  27 21 10-5-10-1 M local p<10-5 for log(EC50)  
Messamore et al. 
2003 
SCH 27 p<0.0001 at 10-3 M; p<0.01 at 10-2 M 
Laser 
Doppler 
flowmetry 
BPD 26 32 0-10
-2 M local 
no significant difference 
Ross et al. 2004 
a score 0-3; b score 1-7; c PP- photoplethysmography; d orally applied niacin, locally applied methyl nicotinate; e simplex fam. – 
family with only one member affected with schizophrenia; f multiplex fam. – family having a sib-pair with schizophrenia;  
SCH –schizophrenia; BPD – bipolar disorder 
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Table 2. Summary of niacin skin-flush studies in other neuropsychiatric diseases and healthy individuals 
Patients Cont. Niacin response -  Method of 
evaluation diagnosis N N 
Dose Appli-cationd absent or diminished skin-flushing 
Reference 
visual 
inspection dyslexia 51 45 10
-4-10-1 M local p<0.01 at 10-4 after 9 min Cyhlarova et al. 2007 
Huntington 
disease 
6 14 10-4-10-1 M local p=0.004 for total skin response (at all conc.) 
Puri 2001 volumetric 
niacin 
resp. autism 8 16 10-4-10-1 M local no significant difference Puri & Singh 2002 
optical 
reflection 
spectrosco
py 
healthy 
individuals - 
63 
males 
54 
female
s 
10-3-10-1 M local 
females reacted stronger  
than males 
p<0.01 at 10-3 M after 6-15 min; 
p<0.05 at 10-2-10-1 M after 6 min 
Smesny et 
al. 2004 
laser 
Doppler 
flowmetry 
social phobia 31 41 0 - 10-2 M local p<0.05 at 10-3-10-2 M Katzman et al. 2003 
a score 1-7 
 
EFFECTS OF ENVIRONMENTAL 
FACTORS, AGE AND SEX ON NIACIN–
INDUCED RESPONSE 
It is well known that schizophrenic patients 
consume significantly more nicotine than the 
healthy population (Leonard et al. 2007, Kohnomi 
et al. 2009). The consequence of nicotine smoking 
is creation of free radicals that reduce the level of 
PUFAs in membrane phospholipids (Thomas, 
2000). It has been proved that nicotine intake may 
induce (Sastry & Hemontolor 1998), but also 
inhibit (Marin et al. 1997) the activity of PLA2. 
Different effects of tobacco smoking on the levels 
of membrane PUFAs are related to the stage of 
illness (acute or chronic), the type of therapy and 
the length of tobacco smoking (Reddy et al. 2004). 
Although a number of studies have investigated 
possible effects of tobacco smoking on the results 
of the niacin test (Mills et al. 1997, Shah et al. 
2000, Smesny et al. 2005, Liu et al. 2007), none of 
them has established a significant effect of tobacco 
consumption. Hibbeln et al. (2003) established a 
link between tobacco smoking habit and type of 
diet in the patients; they found that schizophrenic 
patients who were smokers consumed significantly 
less LA than non-smoking schizophrenic patients. 
Non-smoking female patients consumed more 
DHA than male patients, whether smokers or not. 
The use of cannabis (Smesny et al. 2003, 2005, 
2007a,b), coffee and alcohol (Lin et al. 2007) had 
no significant effect on the intensity of niacin 
response in subjects with schizophrenia but it had 
been shown that regular use of cannabis in healthy 
individuals significantly reduced the niacin 
response (Smesny et al. 2007b). Considering the 
suggested modulation of AA metabolic cascade by 
cannabis, the fact that there is no effect of cannabis 
in schizophrenic patients may indicate an already 
existing metabolic disorder.  
Studies on the effects of antipsychotic drugs 
on the results of the niacin test have yielded 
contradictory results. While the majority of the 
studies reported no influence of antipsychotic 
drugs on niacin sensitivity (Hudson et al. 1997, 
Shah et al. 2000, Messamore et al. 2003, Ross et 
al. 2004), only the study of Tavares et al. (2003) 
revealed a possibility that antipsychotic drugs 
might alter niacin response in a proportion of 
patients undergoing treatment. His group reported 
a significant reduction of phospholipase A2 activity 
after 8 weeks of treatment, as well as a conversion 
of a negative niacin test into positive in 30% of 
schizophrenic patients. Furthermore, there is 
evidence that prolonged use of atypical anti-
psychotics, mood-stabilizers, and antidepressant 
drugs affect similar targets suppressing common 
biochemical pathway(s) such as the phospho-
inositide-protein kinase (PI-PKC) (McNamara et 
al. 2006) and ERK1/2 pathways (Thomas et al. 
2006) which both involve cytosolic PLA2s. These 
results indicate that the niacin test might reveal 
balance/imbalance of membrane phospholipid 
metabolism and serve as a marker of the patient's 
response to psychopharmacotherapy, and conse-
quently predict the odds for remission of the 
disease. There is a need for further systematic 
investigation on possible effects of a prolonged use 
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of antipsychotics on the niacin-induced skin 
flushing in schizophrenic patients, especially in 
terms of monitoring different stages of the illness 
(Smesny et al. 2005). 
There is no evidence that corticosteroids, 
acetylcholine and histamine receptor blockers or 
local anesthetics such as procaine have an effect on 
the skin response to niacin (Wilkin et al. 1985, 
Messamore 2003). On the other hand, a number of 
studies indicate that the dietary addition of PUFAs, 
such as AA and DHA that cannot be synthesized 
de novo in the human body, may influence the 
niacin response by increasing the amount of 
substrate for prostaglandins synthesis (Fenton et al. 
2000, Peet et al. 2001, Emsley et al. 2002).  
The studies of Smesny et al. (2001, 2004) 
recommended a consideration of age and sex in 
clinical studies on niacin sensitivity. The skin 
niacin response diminished with age in both sexes 
(although recognizable at different concentrations 
of the niacin solution), and male sex showed a 
weaker niacin response than female. The effect of 
sex was most pronounced at the lowest niacin 
concentration (0.001M). The authors indicated 
possible effects of sex hormones on vasomotor 
functions and prostaglandin metabolism, but also 
sex-specific variation in skin anatomy or changes 
of skin pigmentation with age that could influence 
the visualisation of niacin-induced redness. The 
differences in pharmacodynamic responses and 
cutaneous penetration were observed between 
black and white races in the study by Berardesca & 
Maibach (1990). 
 
NIACIN SKIN FLUSHING AND 
GENETIC LOADING IN 
SCHIZOPHRENIA 
A number of studies have found a diminished 
niacin-induced skin response in the first-degree 
relatives of patients with schizophrenia (Waldo 
1999, Shah et al. 1999, Lin et al. 2007, Chang et al. 
2009) indicating that they might have a disturbance 
in the metabolism of phospholipids. The study by 
Chang et al. (2009) included the largest number of 
patients with schizophrenia and their first relatives. 
Using visualization methods they found a 
significantly weaker niacin response in patients 
where more relatives also had schizophrenia 
(multiplex families), than in subjects from families 
with only one patient with schizophrenia (simplex 
families) (Table 1). Furthermore, niacin testing 
significantly differentiated between patients from 
simplex families, and control individuals (Chang et 
al. 2009). The authors observed the same pattern of 
niacin response also in the 1st degree relatives 
(parents and siblings) of patients with schizo-
phrenia from multiplex families, compared to 
simplex families, and controls (data not presented 
in Table 1), suggesting a high genetic loading in 
the niacin skin response and etiology of this 
multifactorial disease. The estimated heritability in 
their study ranged from 47% to 54%. However, the 
study of Smesny et al. (2007a) did not find 
evidence of niacin hyposensitivty as a heritability 
trait in schizophrenia (attenuated skin flushing was 
observed in 19 first-episode schizophrenic patients, 
but not in their 21 first-degree relatives). Although 
the sample of Smesny et al. (2007a) was quite 
small to provide relevant conclusions, it should be 
pointed out that the two studies used different 
methods of skin redness evaluation. The results of 
Chang et al. (2009) strongly support the hypothesis 
of the abnormal niacin-induced skin flush response 
as a marker for genetic susceptibility to 
schizophrenia. 
 
DISCUSSION  
Attenuated niacin skin flushing is a robust 
finding in schizophrenia (Table 1). In a number of 
studies, following local application, the niacin-
induced response was evaluated by methods that 
showed similar informative potential. A weak or 
absent response to niacin has been observed in 
neuropsychiatric conditions other than 
schizophrenia. Therefore, a weak or absent 
response to niacin cannot represent a reliable 
diagnostic test for schizophrenia. Nevertheless, the 
niacin response is significantly weaker in 
schizophrenic patients when compared to bipolar 
or depressive (unipolar) patients (Maclean et al. 
2003, Bosveld-van Haandel et al. 2006, Liu et al. 
2007). The significance of this collection of data 
might be that in patients having their first 
psychotic episode, especially in adolescents and 
young adults, an attenuated niacin response in 
combination with psychotic behavior my be 
considered likely to suffer from schizophrenia 
(Ward et al. 1998). Different niacin response in 
schizophrenic and bipolar patients suggests the 
existence of biochemical differences in spite of an 
overlap of clinical symptoms for these two 
diseases. Consequently, the niacin test might help 
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in the differentiation of schizophrenia and other 
psychotic diseases. A reduced volumetric niacin 
response was further observed to parallel higher 
cerebral energy metabolism in violently offending 
patients with schizophrenia, leading to the 
suggestion of an association between lower niacin 
response and severity of illness (Puri et al. 2007).  
Several studies have investigated a correlation 
between clinical symptoms and niacin insensitivity 
in schizophrenia (Maclean et al. 2003, Smesny et 
al. 2003, Smesny et al. 2005, Smesny et al. 2007). 
Only a study by Smesny et al. (2003) found a 
cluster of weak correlations between Brief 
Psychiatric Rating Scale (BPRS) sub-scores and 
visual ratings of skin redness at different niacin 
concentrations, although the significance values 
were not corrected for multiple testing. 
Spectroscopic results obtained by Smesny et al. 
(2003) showed significant correlations with total 
PANSS score and PANSS negative sub-score for 
0.01M niacin solution.  
Since attenuated niacin flushing in 
schizophrenia additionally showed a high genetic 
loading (Lin et al. 2007, Chang et al. 2009), there 
was a possibility that diminished or absent niacin 
flushing represented an intrinsic feature and 
endophenotypic marker in schizophrenic patients. 
The results actually suggest that there was a 
phenotypic subpopulation within the population of 
schizophrenia sufferers that displayed disturbed 
membrane phospholipids metabolism, and the 
niacin test might be important in the identification 
of this subpopulation (Tavares et al. 2003). Glen et 
al. (1996) and Maclean et al. (2003), although with 
contradictory observations, were the only ones that 
investigated the correlation between the niacin test, 
disturbed phospholipid metabolism and 
schizophrenia. While Glen et al. (1996) reported 
that schizophrenic patients with a weak or absent 
skin flushing following niacin application had 
reduced levels of AA and DHA in peripheral cell 
membranes, Maclean et al. (2003) did not find 
evidence for an association between a reduced or 
weak niacin response in patients with 
schizophrenia and any fatty acid deficiency. 
The studies by Ross (2003) and Smesny et al. 
(2005) considered the niacin test as supportive, 
although not conclusive for the membrane 
phospholipid hypothesis of the etiology of 
schizophrenia. Disturbance in the prostaglandin 
signaling cascade may not be necessarily caused 
by PUFA precursor’s deficit. The cause may be at 
the level of niacin receptors, or prostaglandin 
receptors in the blood vessel wall, as well as in 
poor vasomotor activity. A recent postmortem 
finding of a reduced expression of high-affinity 
niacin receptor HM74A in the anterior cingulate 
cortex of individuals with schizophrenia suggests 
possible mechanisms for attenuated niacin skin 
flushing in this illness (Miller & Dulay 2008). 
Genetic studies might help in elucidating the 
individual niacin sensitivity. According to our 
knowledge, only one study investigated the 
association between the niacin skin response and 
genotype (Covault et al. 2004). The authors found 
greater dermal erythema following topical 
application of methyl-nicotinate in patients with a 
T allele of the functional C/T polymorphism in the 
first introne of the X-linked FACL4 gene (long-
chain fatty acid-CoA ligase type 4; Xq22.3). Facl4 
enzyme selectively esterifies AA, DHA and 
eicosapentaenoic acid (EPA) with co-enzyme A, 
forming acyl-CoA, which could be incorporated 
into membrane phospholipids. A statistically 
significant excess of the T allele was found in 198 
subjects with major depression. An excess of the T 
allele, although not significant, was also found in 
58 schizophrenic subjects, while in 70 alcoholics 
no difference was found in comparison to 229 
controls.  
 
CONCLUSIONS 
New biochemical and genetic studies on 
patients with schizophrenia, as well as on other 
psychiatric and neurological patients are needed in 
order to elucidate underlying mechanisms of the 
attenuated skin response to niacin. The importance 
of genetic factors or psychopharmacotherapy in 
skin (in)sensitivity should also be established. It is 
necessary to establish a unique testing and 
evaluation method, providing thus for 
comparability of all the study results; age, sex and 
environmental factors (drug abuse, medication, 
diet) should be stringently controlled.  
By comparing different evaluation methods of 
the niacin-induced skin response and the results 
they yielded (Table 1) we concluded that visual 
inspection is a satisfactory, non-invasive, fast, 
simple, reproducible and cheap method, capable of 
differentiating groups of tested subjects after the 
application of different concentrations of niacin 
solutions (from 10-4 to 10-1 M). The concentration 
of niacin that yielded best differentiation among 
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groups of tested subjects was, in the majority of 
studies 10-3-10-2 M, while recommended duration 
of evaluation of the results was 5-20 minutes in 3-5 
minute intervals. The niacin test suggests to the 
patient that her/his disease is biochemical, which 
can contribute to the development of a positive 
attitude towards medication.  
Based on the reviewed results we concluded 
that niacin (in)sensitivity might be an important 
research tool primarily in schizophrenia, but 
possibly also in other psychiatric and neurological 
diseases. New research is necessary to establish 
whether the niacin skin flush test could serve as a 
diagnostic marker used as an auxiliary method, 
together with the existing diagnostic criteria, and 
for follow-up of the psychic (and/or biochemical) 
status of patients (i.e. at admission and during 
pharmacotherapy evaluation).  
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